Novartis AG Cash Conversion Cycle 2011-2026 | NVS

Annual Cash Conversion Cycle Novartis AG

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	0.04	0.04	-	104	88.1	84	99.2	102	94.2

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
104	0.04	71.4

Cash Conversion Cycle of other stocks in the Biotechnology industry

Issuer	Cash Conversion Cycle	Price	% 24h	Market Cap	Country
Heron Therapeutics HRTX	751	$ 0.8	2.7 %	$ 133 M	USA
Amphastar Pharmaceuticals AMPH	205	$ 19.23	-1.38 %	$ 899 M	USA
Altimmune ALT	7.85 K	$ 3.44	2.99 %	$ 303 M	USA
Aytu BioScience AYTU	174	$ 2.63	0.77 %	$ 16.5 M	USA
I-Mab IMAB	-1.97 K	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	12.8	-	-	$ 40.3 B	USA
Midatech Pharma plc MTP	82.8	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	17	-	-1.52 %	$ 24.7 M	USA
Incyte Corporation INCY	-54.7	$ 90.45	-0.36 %	$ 17.7 B	USA
Inovio Pharmaceuticals INO	1.91 K	$ 1.61	1.9 %	$ 35.7 M	USA
Aeterna Zentaris AEZS	-34.3 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-8.96 K	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	117	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	-1.55 K	-	-0.23 %	$ 916 M	USA
Acasti Pharma ACST	1.97	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	104	-	-	-	Russia
Advaxis ADXS	-143 K	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	-2.15 K	-	-	$ 7.46 M	Israel
BioDelivery Sciences International BDSI	340	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	52.6	-	0.49 %	$ 251 B	Cayman-islands
Kamada Ltd. KMDA	163	$ 8.2	-0.61 %	$ 260 M	Israel
Calithera Biosciences CALA	28.8	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	52.4	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	3.1	-	-	$ 3.74 B	USA
Karyopharm Therapeutics KPTI	72.5	$ 6.66	-12.71 %	$ 812 K	USA
Keros Therapeutics KROS	4.72	$ 11.24	2.55 %	$ 418 M	USA
Clovis Oncology CLVS	65.5	-	-7.23 %	$ 13 M	USA
Longeveron LGVN	-212	$ 0.95	-2.71 %	$ 16.7 B	USA
Denali Therapeutics DNLI	1.89	$ 21.09	4.56 %	$ 3.47 B	USA
Arbutus Biopharma Corporation ABUS	31.5	$ 4.42	4.25 %	$ 734 M	Canada